A combination of the ferroptosis inducer RSL-3 and dihydroartemisinin (DHA), an immunotherapy medicine targeting PD-L1, was designed for the treatment of pancreatic ductal adenocarcinoma (PDAC) [38]. The gene discussed is CD274; the disease is pancreatic ductal adenocarcinoma.